Guggenheim Stays Bullish on Cigna (CI) With Updated $318 Price Target

The Cigna Group (NYSE:CI) is included among the 14 Best US Stocks to Buy for Long Term.

On December 2, Guggenheim lifted the firm’s price target on The Cigna Group (NYSE:CI) to $318 from $309 and maintained a Buy rating on the stock.

In its earnings for the third quarter of 2025, The Cigna Group (NYSE:CI) announced that it is addressing some of the biggest challenges in the healthcare industry, and for that, the company unveiled a new pharmacy benefit model that eliminates rebates, with cost reductions and increased transparency, while helping local pharmacies. Overall, Cigna Group reported a 10% YoY growth in its revenues at $69.7 billion in Q3. The revenue also beat analysts’ estimates by $3 billion.

The Cigna Group (NYSE:CI)’s Evernorth Health Services, which includes Pharmacy Benefit Services and Specialty and Care Services operating segments, was the main contributor to the revenue growth. The segment’s adjusted revenue and adjusted income from operations grew by 15% and 1%, respectively.

The Cigna Group (NYSE:CI) is an American multinational managed healthcare and insurance company that offers a wide range of related services and products.

While we acknowledge the potential of CI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Blue Chip Dividend Stocks to Build a Passive Income Portfolio and 15 Dividend Stocks That Outperform the S&P 500.

Disclosure: None.